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Crystal Structure of the PTEN Tumor Suppressor:
Implications for Its Phosphoinositide Phosphatase
Activity and Membrane Association
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noma cases (reviewed in Maehama and Dixon, 1999).
In addition, germline mutations in PTEN are associated
with the dominantly inherited Cowden and Bannayan-
Zonana syndromes, which are characterized by the for-
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risk of malignant breast and thyroid tumors. Heterozy-2Howard Hughes Medical Institute
gous disruption of PTEN in mice leads to neoplasia in3Department of Human Genetics and Molecular Biology
multiple tissues reminiscent of human Cowden diseaseProgram
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And in NIH 3T3 fibroblasts, PTEN can suppress cell5Laboratory of Molecular Oncology
migration, spreading, and the formation of focal adhe-The Rockefeller University
sions (Tamura et al., 1998).New York, New York 10021
The 403±amino acid PTEN protein contains the signa-6Department of Biological Chemistry
ture motif HCXXGXXR present in the active sites of pro-University of Michigan
tein tyrosine phosphatases (PTPs) and dual specificityAnn Arbor, Michigan 48109
protein phosphatases (DSPs), but it has little sequence7Department of Molecular Biology
homology to these protein families outside this motif.Princeton University
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PTEN encompassing the signature motif has homology
to tensin and auxilin (Li et al., 1997; Steck et al., 1997).
Tensin is an actin-binding protein localized to focal ad-
Summary hesion complexes, and auxilin is involved in the uncoat-
ing of clathrin-coated vesicles. Beyond the tensin/auxi-
The PTEN tumor suppressor is mutated in diverse hu- lin/phosphatase homology domain, PTEN contains an
man cancers and in hereditary cancer predisposition z220±amino acid carboxy-terminal region whose func-
syndromes. PTEN is a phosphatase that can act on tion has not been clear. Tumor-derived mutations map
both polypeptide and phosphoinositide substrates in evenly to the two domains, and mutations in either do-
vitro. The PTEN structure reveals a phosphatase do- main have been shown to reduce or eliminate PTEN's
main that is similar to protein phosphatases but has growth suppression activity (Furnari et al., 1998; Georg-
an enlarged active site important for the accommoda- escu et al., 1999).
tion of the phosphoinositide substrate. The structure PTEN can dephosphorylate tyrosine-, serine-, and
also reveals that PTEN has a C2 domain. The PTEN threonine-phosphorylated peptides, and this activity re-
C2 domain binds phospholipid membranes in vitro, quires highly acidic substrates (Myers et al., 1997). The
and mutation of basic residues that could mediate focal adhesion kinase (FAK) has been shown to be a
this reduces PTEN's membrane affinity and its ability substrate of PTEN in vitro (Tamura et al., 1998). Recent
to suppress the growth of glioblastoma tumor cells. studies have shown that PTEN can also dephosphorylate
phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3) inThe phosphatase and C2 domains associate across
vitro, with specificity for the phosphate group at the D3an extensive interface, suggesting that the C2 domain
position of the inositol ring (Maehama and Dixon, 1998).may serve to productively position the catalytic do-
PI(3,4,5)P3 is a lipid second messenger produced by themain on the membrane.
phosphoinositide 3-kinase (PI3K) and activates down-
stream effectors. These include the Akt/PKB kinase thatIntroduction
has potent antiapoptotic and growth stimulatory effects.
A role for the PI(3,4,5)P3 phosphatase activity of PTENMutation of the tumor suppressor PTEN/MMAC1 (Li et
in its tumor suppressor function has been supported byal., 1997; Steck et al., 1997) is a common event in diverse
several observations. Tumor cell lines with mutant PTENhuman cancers, occurring in about 50% of glioblastoma,
have elevated levels of PI(3,4,5)P3 and of Akt activity
(Stambolic et al., 1998), and the introduction of wild-
type PTEN reduces levels of both (Li and Sun, 1998). In8 To whom correspondence should be addressed (e-mail: nikola@
C. elegans, a pathway that contains the PI3 kinase andxray2.mskcc.org).
Akt homologs also contains the DAF-18 gene that has9 These authors contributed equally to this work.
10 These authors contributed equally to this work. homology to PTEN (Ogg and Ruvkun, 1998). Finally, the
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Figure 1. PTEN Has an N-Terminal Phosphatase Domain and a C-Terminal C2 Domain
(A) Overall view of the PTEN structure. The dotted line indicates the region deleted in the crystallized protein.
(B) Conservation of PTEN and histogram of 93 missense (red bars) and 80 chain termination (green bars) tumor-derived mutations. The
alignment of C2 domains, obtained with the program PSI-BLAST (Altschul et al., 1997) and THREADER2 (Miller et al., 1996), may not be reliable
outside regions of apparent sequence homology. The structural homology with the VHR and PTP1B phosphatase domains is indicated with
boxes around VHR and PTP1B sequences, and the sequence identity is highlighted in blue. Residues in the deleted loop are shown in
lowercase.
Gly129Glu tumor-derived mutation that maps to the an internal loop (residues 286±309; Figure 1B; data not
shown). Initial crystals, obtained using PTEN truncatedphosphatase signature motif eliminates PTEN's lipid
phosphatase activity but not its protein phosphatase at its termini (residues 7±353), diffracted poorly. There-
fore, the 24-residue protease-sensitive loop was alsoactivity (Furnari et al., 1998; Myers et al., 1998).
Here, we describe the 2.1 AÊ crystal structure of human deleted from the recombinant clone. This truncated
PTEN bound to L(1)-tartrate (Figure 1A) and discuss the PTEN protein has in vitro PI(3,4,5)P3 phosphatase activ-
implications this structure, in conjunction with our in ity similar to that of full-length PTEN (Kcat/KM of 24.0
vitro membrane binding, mutagenesis, and growth sup- min21mM21 and 17.3 min21mM21 for truncated and full-
pression data, have for our understanding of PTEN's length PTEN, respectively); its in vitro membrane affinity
phosphatase activity, its association with the mem- is comparable to that of full-length PTEN (discussed
brane, and its inactivation by mutations in cancer. later); and its apoptosis inducing activity is essentially
identical to that of full-length PTEN when transfected
into LNCaP cells, a PTEN-deficient prostate cancer cellResults and Discussion
line (data not shown). The truncated PTEN was crystal-
lized from Na/K L(1)-tartrate, and its structure was de-Structure Determination
termined at 2.1 AÊ resolution. An L(1)-tartrate molecule,Proteolytic digestion indicated that PTEN has unstruc-
which inhibits the PTEN activity with a Ki of z15 mMtured or loosely folded regions of 7 and 49 residues at
the N and C termini, respectively, and of 24 residues in (data not shown), is bound in the active site (Figure 2D).
Crystal Structure of PTEN
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Figure 2. The PTEN Phosphatase Domain Has the Same Fold as the Dual Specificity Phosphatase VHR, but the Structure Differs around the
Active Site
(A) Superimposition of the PTEN phosphatase domain and VHR structures. The structural elements around the active site that differ in the
two structuresÐthe pb2-a1, ªTIº, and ªWPDº loopsÐare in blue for PTEN and green for VHR.
(B) Slice of the active site molecular surface, represented as a wire mesh, shows the larger size of the PTEN active site pocket compared to
VHR and PTP1B. View is rotated approximately 1808 about the vertical axis of Figure 2A.
(C) Comparison of the active site structural elements and active site residues of PTEN, VHR, and PTP1B. Blue, green, and magenta spheres
near the catalytic Cys-124 indicate the positions of a carboxylate carbon of tartrate in PTEN, the sulfur atom of sulfate in VHR, and the
phosphorous atom of phosphotyrosine in PTP1B, respectively. PTEN residues are labeled, and residues of VHR and PTP1B are labeled only
when they differ from PTEN. Orientation as in Figure 2B.
(D) Close-up view of the PTEN active site, showing the contacts made with the tartrate molecule (green dotted lines). Fo-Fc difference electron
density around the tartrate molecule is shown in magenta. The map was calculated at 2.1 AÊ using a PTEN model before any tartrate atoms
were built; it was contoured at 2.5 s.
Overall Structure of PTEN larger size of the pocket would be important in accom-
modating a PI(3,4,5)P3 substrate. The C-terminal domainThe PTEN structure consists of a 179-residue N-terminal
domain (residues 7±185) and a 166-residue C-terminal has a structure similar to the C2 domain that mediates
the Ca21-dependent membrane recruitment of sev-domain (residues 186±351; Figures 1A and 1B). The
N-terminal domain contains the PTP signature motif and eral signaling proteins, such as the phosphoinositide-
specific phospholipase Cd1 (PLCd1), phosphoinositidehas a structure similar to the dual specificity phospha-
tase VHR. However, the phosphatase active site of PTEN 3-kinase (PI3K), and protein kinase C (PKC) (reviewed
in Rizo and Sudhof, 1998). The PTEN C2 domain lacksis larger than those of VHR and the protein tyrosine
phosphatase PTP1B, and residues responsible for this the canonical Ca21 ligands, and in this respect it is similar
to the C2 domains of the Ca21-independent PKC iso-structural feature are conserved in PTEN homologs. The
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types (Rizo and Sudhof, 1998). The C2 and phosphatase allowing both phospho-tyrosine and the shorter phos-
pho-serine/threonine substrates to reach the catalyticdomains associate across an extensive interface that is
adjacent to the phosphatase active site and consists of cysteine at the bottom, while the deeper PTP1B pocket
permitting only phospho-tyrosine to reach (Yuvaniyamaconserved residues frequently mutated in cancer.
et al., 1996). The wider opening of PTEN's pocket is
consistent with its ability to dephosphorylate phospho-
Structure of the Phosphatase Domain serine/threonine substrates in addition to phosphotyro-
The structure consists of a central five-stranded b sheet sine (Myers et al., 1997).
that packs with two a helices on one side and four on
the other. This overall structure is similar to the dual
Active Site Residues
specificity phosphatase VHR (Yuvaniyama et al., 1996),
In the PTEN HCXXGXXR motif, the Cys-124 and Arg-
and the two structures can be superimposed with an
130 residues that are essential for catalysis and the
rmsd of 1.75 AÊ for 121 Ca atoms (Figure 2A). There are
His-123 and Gly-127 residues that are important for the
several differences in the two structures, and some of
conformation of the P loop (Barford et al., 1994; Stuckey
these map near the active site. Relative to VHR, PTEN
et al., 1994) have the same position and conformation
has an 11-residue insertion (residues 42±52) in the pb2-
as in the PTP1B±substrate complex (Figures 2C and
a1 loop and a 4-residue insertion (residues 163±166)
2D). In addition, Asp-92 of the PTEN ªWPDº loop is in
in the pa5-a6 loop (henceforth ªTIº loop to reflect the
an identical position as the corresponding PTP1B Asp-
conserved threonine and isoleucine residues) (Figures
181 (Figure 2C), which serves as a general acid to facili-
1B and 2A). These PTEN insertions are also absent from
tate protonation of the phenolic oxygen atom of the
the tyrosine phosphatase PTP1B structure (Jia et al.,
tyrosyl leaving group (Jia et al., 1995). Similar to the
1995), although the phospho-tyrosine recognition loop
mammalian PTPs, mutation of Asp-92 to Ala in PTEN
of PTP1B has a position similar to the PTEN pb2-a1
results in a 700-fold reduction in catalytic activity toward
insertion (Figure 2C).
PI(3,4,5)P3 (data not shown). These observations sug-
gest that PTEN binds and hydrolyses the phosphate
ester with a mechanism similar to that of PTP1B.Active Site Pocket
The P loop sequence of PTEN is unique among knownThe PTEN HCXXGXXR signature motif forms a loop (P
PTPs in that it has two basic residues (Lys-125 and Lys-loop, residues 123±130) located at the bottom of the
128) in its center. This PTEN motif, H-C-K/R125-A-G-K128-active site pocket, in common with PTPs and DSPs.
G-R, is conserved in yeast homologs of PTEN as wellThe walls of the pocket are made up of side chain and
(reviewed by Maehama and Dixon, 1999). These lysinebackbone groups from the P loop, the pb4-a3 loop (resi-
residues, together with His-93 of the ªWPDº loop, alsodues 91±94; ªWPDº loop following the PTP1B nomencla-
invariant across species, give the PTEN pocket a highlyture), and the ªTIº loop. The PTEN pocket is z8 AÊ deep
basic character that would be mostly absent fromwith an elliptical opening of z5 3 11 AÊ . Compared to
PTP1B or VHR (Figure 4C). The positive charge in theVHR, the PTEN pocket is both wider and deeper; com-
pocket is consistent with the negative charge of thepared to PTP1B it is about twice as wide but has a
PI(3,4,5)P3 substrate and with PTEN's preference forsimilar depth (Figure 2B).
highly acidic polypeptide substrates (Myers et al., 1997).The larger width of the pocket compared to PTP1B
and VHR is primarily due to the ªTIº loop of PTEN. This
loop, which contains a conserved 4-residue insertion Bound Tartrate Molecule
At one end of the L(1)-tartrate molecule, a carboxylaterelative to PTP1B and VHR, has a structure that is dis-
placed away from the center of the pocket by several group and the adjacent hydroxyl group bind over the
active site Cys-124, making hydrogen bonds to back-angstroms (Figure 2C). This results in an extension to
the pocket, with the conserved Val-166±Thr-167±Ile-168 bone amide groups and to the side chains of the Cys-
124 and Arg-130 of the P loop (Figure 2D). The carboxyl-residues forming the side wall of this extension (Figure
2D). The ªTIº loop has a rigid conformation stabilized ate and hydroxyl groups are at a very similar position
as the phosphate group of the phosphotyrosine sub-by contacts to the rest of the phosphatase domain and
is adjacent to the C2 domain. The larger width of the strate in PTP1B, and their contacts to the active site
closely reproduce the array of contacts made by thePTEN pocket is consistent with the larger size of the
PI(3,4,5)P3 substrate compared to phospho-tyrosine, phosphate group in the PTP1B±substrate structure (Jia
et al., 1995).serine, or threonine substrates. The importance of the
pocket extension in PTEN's PI(3,4,5)P3 phosphatase ac- The carboxylate and hydroxyl groups at the other end
of the tartrate molecule bind in the part of the PTENtivity can be seen in the Gly129Glu tumor-derived muta-
tion, which disrupts PTEN's PI(3,4,5)P3 phosphatase ac- pocket that corresponds to an extension relative to the
pockets of PTP1B and VHR, and partially fill this exten-tivity but maintains the tyrosine phosphatase activity
(Furnari et al., 1998; Myers et al., 1998). Gly-129 is at sion. This carboxylate group makes three hydrogen
bonds with backbone amide groups on the P loop andthe bottom of the pocket, near the extension, and the
structure suggests that this mutation would reduce the the ªWPDº loop, and with the Gln-171 side chain from
the ªTIº loop (Figure 2D). The adjacent hydroxyl groupsize of PTEN pocket extension (Figures 2B and 2C).
It has been suggested that the depth of the active makes two more hydrogen bonds with a backbone am-
ide group and Asp-92 side chain from ªWPDº loop (Fig-site pocket is an important determinant of the phospho±
amino acid specificity, the shallow pocket of VHR ure 2D). These interactions suggest that PTEN has a
Crystal Structure of PTEN
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Figure 3. Model of Ins(1,3,4,5)P4 Binding to the PTEN Active Site
(A) The phosphate groups at the D3 and D4 positions of Ins(1,3,4,5)P4 (PDB entry 1bwn) are superimposed on the carboxylate groups of the
tartrate molecule bound in the PTEN active site. Orientation as in Figure 2B.
(B) Model of PTEN-Ins(1,3,4,5)P4 complex. Side chains that are important for Ins(1,3,4,5)P4 binding are shown.
(C) Lipid phosphatase activity of human PTEN mutants. PI(3,4,5)P3 was incubated with 100 ng of recombinant PTEN or GST-PTEN (labeled
with *) for 1 min. PI(3,4)P2 and PI(3)P were incubated with 1 mg of PTEN for 5 and 7 min, respectively. The GST-fusion protein shows essentially
identical enzymatic activity with the nonfusion protein (data not shown).
(D) Normalized lipid phosphatase activity of human PTEN mutants. Initial rate of phosphoinositide phosphatase (PIPx ptase) activity toward
PI(3,4,5)P3, PI(3,4)P2, and PI(3)P was divided by that of the pNPPase activity. The activity of wild-type PTEN toward each of the substrates is
normalized to 100%. Other percentage activities represent ratios of wild-type versus mutants. n.d., not determined.
second anion-binding site adjacent to the catalytic structure obtained from the Protein Data Bank. In this
superposition, the D5 phosphate group ends up next tophosphate-binding site.
the conserved Lys-128 and His-93 side chains. The D1
phosphate group ends up next to the conserved Lys-Implications for PI(3,4,5)P3 Binding
125, pointing away from the active site and available forThe 4.3 AÊ distance between the two carboxylate carbon
attachment to the lipid (Figure 3B).atoms of tartrate is very similar to the 4.1 AÊ distance
between the phosphorus atoms at the D3 and D4 positions
of inositol (1,3,4,5)-tetrakisphosphate (Ins(1,3,4,5)P4) (Bar- Mutagenesis of Pocket Residues
Because the pocket extension and the basic charge inaldi et al., 1999). This suggests the model that PI(3,4,5)P3
may bind with the D3 phosphate group at the catalytic the active site of PTEN distinguish it from known protein
phosphatase structures, we mutated the residues re-site and the D4 phosphate group in the second anion-
binding site. When the D3 and D4 phosphate groups sponsible for these features and tested their effects on
PTEN's PI(3,4,5)P3 phosphatase activity.of Ins(1,3,4,5)P4 are superimposed on the carboxylate
groups of tartrate, the D5 phosphate group occupies On the ªTIº loop, mutation of Thr-167 or Gln-171 re-
sulted in reductions of 60% and 75%, respectively, inthe remaining space in the pocket extension (Figures
3A and 3B). This results in a snug fit of the D3, D4, and the activity of the enzyme toward PI(3,4,5)P3 (Figure 3C).
In the crystal structure, the Thr-167 side chain is solventD5 phosphate groups in the pocket without any steric
clashes and without any adjustment in the Ins(1,3,4,5)P4 exposed and has no apparent structure-stabilizing role.
Cell
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The Gln-171 side chain is partially solvent exposed and (CBR1, CBR2, and CBR3 loops) (reviewed by Rizo and
Sudhof, 1998), and this has been implicated in mediatinghydrogen bonds to one of the carboxylate groups of
tartrate (Figure 2D). The reduction in the enzymatic activ- and regulating their membrane association (Essen et al.,
1997; Perisic et al., 1998; Sutton and Sprang, 1998). Theity resulting from their mutation thus suggests that the
pocket extension where these residues occur plays an PTEN C2 domain differs from these C2 domains in that
it lacks all but one (Asp-268) of the Ca21 ligands and isimportant role in PI(3,4,5)P3 binding. In our PTEN±
Ins(1,3,4,5)P4 model, Thr-167 and Gln-171 are in the vi- thus unlikely to bind Ca21.
As it lacks the Ca21 ligands, the PTEN C2 domain iscinity of the phosphate groups at the D4 and D5 posi-
tions (Figure 3B). unlikely to bind membranes in a Ca21-dependent man-
ner. However, there are several analogies between theWe next tested the effects of mutating the conserved
basic residues in the PTEN active site. A Lys125Met proposed membrane-interacting portions of the Ca21-
dependent C2 domains and the corresponding regionsmutation in the PTEN active site motif, H-C-K/R125-A-
G-K128-G-R, resulted in a reduction of enzyme activity of the PTEN C2 domain. PTEN has a CBR3 loop that
has the same structure as in the Ca21-dependent C2toward PI(3,4,5)P3, as well as toward the poorer (Myers
et al., 1998) substrates PI(3,4)P2 and PI(3)P (Figure 3C). domains (Figures 4A and 6B). The structure of this loop
extends perpendicularly away from the membrane-fac-This result is consistent with our model, where Lys-125
would be in close proximity to the phosphate group at ing sheet of the Ca21-dependent C2 domains, and this
structural feature has been suggested to play a centralthe D1 position. However, this mutation also reduced the
phosphatase activity towards p-nitrophenyl phosphate role in membrane binding (Essen et al., 1997; Perisic et
al., 1998). The CBR3 loop of PTEN has a net 15 positive(pNPP), a phosphatase substrate analog, and it is con-
ceivable that Lys-125 may have additional roles. By con- charge resulting from the solvent-exposed Lys-260, Lys-
263, Lys-266, Lys-267, Lys-269, and the partially buriedtrast, mutation of Lys-128 to methionine reduced the
PI(3,4,5)P3 phosphatase activity by 85% while slightly His-259±Asp-268 pair (Figures 1B and 4C). This positive
charge could be similar to the positive charge resultingelevating the pNPPase activity (Figure 3C). This mutation
had a modest effect on PTEN activity with the other D3- from Ca21 binding to the CBR3 loops of the Ca21-depen-
dent C2 domains, where the charge has been implicatedphosphorylated substrates [PI(3,4)P2 and PI(3)P] (Figure
3C). Data normalized against pNPPase activity clearly in their affinity for the phospholipid phosphoryl groups
(Essen et al., 1997). PTEN also contains two solvent-show that the reduction in the phosphatase activity is
specific for the PI(3,4,5)P3 substrate (Figure 3D). Among exposed hydrophobic residues, Met-264 and Leu-265,
at the CBR3 tip (Figure 1B). This is a position wherethese substrates, only PI(3,4,5)P3 has a phosphate group
at the D5 position, and these data are consistent with about half of the known C2 domains contain at least
one hydrophobic residue (Perisic et al., 1998); based inan interaction between Lys-128 and the D5 phosphate
group (Figure 3B). In support of this model, mutation of part on fluorescence data with synaptotagmin (Chap-
man and Davis, 1998), the hydrophobic residue(s) hasLys-128 to an arginine did not reduce the enzymatic
activity (Figure 3C). been proposed to insert into the lipid bilayer (Chapman
and Davis, 1998; Bittova et al., 1999). Finally, the PTENMutation of His-93 of the ªWPDº loop had similar
effects as the mutation of Lys-128, reducing the PI(3, C2 domain has an additional basic patch on the adjacent
ca2 helix, resulting from the solvent-exposed Lys-327,4,5)P3 phosphatase activity by 75% while having only
a modest effect on the PI(3,4)P2 phosphatase activity Lys-330, Lys-332, and Arg-335 (Figures 1B and 4C). This
is a position similar to a helix of cPLA2 that has been(Figure 3C). This result is also consistent with our model,
where His-93 is in close proximity to the phosphate implicated in contributing to membrane binding (Perisic
et al., 1998).group at the D5 position (Figure 3B). This finding helps
explain the high frequency of mutation of His-93 in can- These nine basic and two hydrophobic side chains
emanating from the CBR3 and ca2 elements of the PTENcer (Figure 1B).
C2 domain are on the same face as and in close proxim-
ity to the phosphatase active site (Figure 4C), consistentStructure of the PTEN C2 Domain
with a possible role in membrane association.The C-terminal 170 amino acids fold into a b sandwich
structure consisting of two antiparallel b sheets with
two short a helices intervening between the strands C2 Domain Has Affinity for Phospholipid
Membranes In Vitro(Figures 1A and 1B). The PTEN b sandwich has a topol-
ogy identical to the type II topology of the C2 fold, and Because of these analogies, we tested whether the
PTEN C2 domain has affinity for phospholipid mem-its structure is similar to the C2 domains of PLCd1, PKCd,
and phospholipase A2 (cPLA2) (Essen et al., 1996; branes in vitro. We measured membrane binding using
multilamellar phospholipid vesicles consisting of phos-Pappa et al., 1998; Perisic et al., 1998). It can be superim-
posed on the C2 domain of cPLA2 with an rms deviation phatidyl choline (PC), according to published proce-
dures (Davletov et al., 1998). Figure 4B shows that PTENof 1.9 AÊ for 85 Ca atoms, and with similar rms deviations
on the PKCd (1.7 AÊ /67 Ca) and PLCd1 (1.9 AÊ /75 Ca) C2 and the PTEN C2 domain fused to the GST protein bind
the vesicles under conditions where several control pro-domains (Figure 4A). These rms deviations are compara-
ble to those reported between the more divergent mem- teins do not show detectable binding. In the positive
control, the C2 domain of synaptotagmin bound thebers of the C2 family, such as the PKCd and synaptotag-
min C2 domains (1.7 AÊ /85 Ca) (Pappa et al., 1998). vesicles in a Ca21-dependent manner, as reported (Dav-
letov and Sudhof, 1993). As expected, the in vitro mem-The C2 domains of PLCd1, PKCb, cPLA2, and synap-
totagmin I (SynI) can bind Ca21 through three loops brane binding activity of PTEN does not require Ca21.
Crystal Structure of PTEN
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Figure 4. The C-Terminal Half of PTEN Has a C2 Domain of Type II Topology
(A) Stereo view of the Ca traces of the superimposed C2 domains of PTEN (red) and PLCd1 (green).
(B) The PTEN C2 domain has affinity for phospholipid vesicles. Representative Coomassie-stained gel of proteins bound to pure phosphatidyl
choline (PC) or phosphatidyl serine (PS) containing (at a PS:PE:PC ratio of 35:50:15) large multilamellar vesicles is shown. The lipid vesicles
were prepared according to published procedures (Davletov et al., 1998). Bar graphs show the amount of bound protein relative to the total
protein. PTEN-FL is full-length PTEN, PTEN-cryst. is the crystallized PTEN fragment, PTEN(C2) is a GST fusion protein of the PTEN C2 domain,
and p53 is the DNA-binding domain of the p53 protein. PTEN(C2) has a tendency to aggregate, and this may contribute to its lower membrane
binding activity in this assay. It is also conceivable that the phosphatase domain contributes to membrane binding. The isolated phosphatase
domain could not be overexpressed in a soluble form. Where indicated, Ca21 or EDTA was included at 2 mM.
(C) Surface electrostatic potential of PTEN. The top view is rotated z908 about the horizontal axis of Figure 4A, so that the CBR3 loop is
extending approximately out of the plane of the figure. Tartrate is in yellow.
Proposed Membrane-Binding Elements of the PTEN in the CBR3 and ca2 elements of the C2 domain and
tested the growth suppression activity of these PTENC2 Domain Are Important for Its Tumor
Suppressor Function mutants in vivo and their membrane affinity in vitro. In
the M-CBR3 mutant, we replaced the sequence 263-K-To investigate the significance of PTEN's in vitro mem-
brane affinity, we mutated the solvent-exposed residues M-L-K-K-D-K-269, which contains four of the five lysine
Cell
330
Figure 5. Inhibition of the Tumor Suppressor
Activity of PTEN by Mutations in the Lipid-
Binding C2 Regions
(A) Morphological changes and (B) anchor-
age-independent growth of retrovirus-infected
U87-MG glioblastoma cells stably expressing
PTEN and mutants. pCX is the retroviral vec-
tor without an insertion; PTEN is the wild-type
PTEN; L345Q and H93A are tumor-derived
mutations; M-ca2 and M-CBR3 contain the
mutations described in the text. The photo-
graphs of the cells growing in plate and of the
colonies developed in soft agar were taken at
203 and 103 magnification, respectively.
(C) Proliferation of the same cells. The num-
ber of retrovirus-infected cells surviving after
the drug selection is shown. Infection effi-
ciency of the virus was near 100%, and es-
sentially no cells died during the drug
selection.
(D) Protein expression levels for PTEN and
mutants. Proteins (50 mg) from lysates of sta-
bly transfected U87-MG cells were resolved
by SDS-polyacrylamide gel electrophoresis
and analyzed by Western blotting with an
anti-Myc antibody recognizing Myc-tagged
PTEN and mutants.
(E) The PI(3,4,5)P3-phosphatase activity of
wild-type and mutant PTEN proteins immu-
noprecipitated from U87-MG cells using a
short-chain, water-soluble PI(3,4,5)P3. The
amounts of immunoprecipitated proteins an-
alyzed by Western blotting were comparable
for wild-type PTEN, H93A, H123Y, M-ca2, and
M-CBR3 mutants and were lower for the
L345Q mutant (data not shown). These re-
sults were also reproduced with the recombi-
nant GST-PTEN fusion proteins purified from
E. coli (data not shown).
(F) M-ca2 and M-CBR3 mutants have re-
duced affinity for phospholipid vesicles. Rep-
resentative Coomassie-stained gel of proteins
bound to multilamellar vesicles containing
phosphatidyl choline is shown. The lipid vesi-
cles were prepared according to published
procedures (Fukuda et al., 1996). The lanes
labeled with P and S represent the pellet and
supernatant fractions, respectively.
and both hydrophobic tip residues of the CBR3 loop, al., 1999), the proliferation and anchorage-independent
growth of U87-MG glioblastoma tumor cells were sup-with the 263-A-A-G-A-A-D-A-269 sequence. The mu-
tated residues are entirely solvent exposed and have pressed in the presence of wild-type PTEN, while the
tumor-derived mutants His123Tyr and Leu345Gln al-no apparent structure-stabilizing roles. Asp-268 was not
mutated, as it is partially buried and makes a salt bridge lowed the growth of these cells (Figures 5A±5C). The
cells expressing the His123Tyr mutant proliferated ex-with His-259. In the M-ca2 mutant, we replaced the
sequence 327-K-A-N-K-D-K-A-N-R-335 with 327-A-A- tensively in clusters lacking cell±cell contact inhibition
and formed large colonies in the soft agar assay similarG-A-D-A-A-N-A-335, again none of the mutated resi-
dues having any apparent structure stabilizing roles. to control vector-transfected cells, while the Leu345Gln
mutant in the C2 domain presented an intermediate tu-Asp-331 was not mutated, as it stabilizes a turn at the
end of the ca2 helix through backbone hydrogen bonds mor growth phenotype (Figures 5A±5C). The M-CBR3
and M-ca2 mutations reduced the growth suppressionand is also mutated in cancer.
The M-CBR3 and M-ca2 mutants were cloned in the activity of PTEN to an extent comparable to that of the
tumor-derived Leu345Gln mutant. The cells expressingpCX retroviral vector and stably expressed in U87-MG
PTEN-deficient glioblastoma cells. For comparison, we the M-CBR3 and M-ca2 mutants proliferated better than
wild-type PTEN-expressing cells and also lacked con-also used the tumor-derived mutants His123Tyr of the
phosphatase active site and Leu345Gln of the C2 do- tact inhibition although not to the same extent as control
cells (Figures 5A and 5C). When seeded in soft agar,main hydrophobic core, both of which were previously
studied with the same assay. As reported (Georgescu et these cells demonstrated anchorage-independent growth,
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Figure 6. The PTEN Phosphatase and C2 Domains Pack across an Extensive Interface that Is Targeted by Tumorigenic Mutations
(A) The interface consists of the ªWPDº loop, ªTIº loop, and pa6 helix from the phosphatase domain (blue), and cb5, cb6, ca1, and ca2 from
the C2 domain (magenta). The hydrogen bond networks in the interface are shown as green dotted lines.
(B) Superposition of PTEN (red) and PLCd1 (green). Their C2 domains are shown as backbone traces, and their respective catalytic domains
as dot surfaces. The active sites in both cases are located on the same face with the CBR3 loops.
giving rise to colonies of intermediate size between We also tested the growth suppression activity of the
tumor-derived His93Ala mutation, whose in vitro bio-those formed by wild-type PTEN and the vector control
(Figure 5B). chemical characterization indicated that His-93 may
have a role in binding the D5 phosphate of PI(3,4,5)P3.Because structural mutations in the C2 domain, such
as Leu345Gln, were shown to induce the rapid degrada- Cells expressing the His93Ala mutant proliferated exten-
sively in clusters lacking cell±cell contact inhibition andtion of PTEN in cells (Georgescu et al., 1999), we
checked the expression level of our mutants in total cell formed large colonies in soft agar similar to control vec-
tor-transfected cells (Figures 5A±5C). Since this muta-lysates from the U87-MG cells. The M-CBR3 and M-ca2
mutants were present at levels essentially identical to tion reduced PTEN's in vitro PIP(3,4,5)P3 phosphatase
activity by 75% while preserving the phosphatase activ-that of wild-type PTEN (Figure 5D), indicating that the
reduction in their growth suppression was not due to ity toward D3 phosphorylated phosphoinositides lacking
the phosphate in the D5 position (Figure 3C), this resultdecreased protein levels in the cells. This also confirmed
our structure-based conclusion that the residues we suggests that the dephosphorylation of PIP(3,4,5)P3 is
more important than the dephosphorylation of PIP(3,4)P2mutated do not have any structure-stabilizing roles. We
also tested the ability of these PTEN mutants immuno- or PIP(3)P for the tumor suppressor function of PTEN.
precipitated from cells to dephosphorylate a soluble,
short-chain PI(3,4,5)P3 analog, using published proce- Phosphatase±C2 Interface
The domain±domain interface buries a surface area ofdures (Georgescu et al., 1999). Figure 5E shows that the
M-CBR3 and M-ca2 mutants have phosphatase activity 1400 AÊ 2 and involves several structural elements from
each domain, including parts of the ªWPDº and ªTIºlevels similar to that of wild-type PTEN.
Finally, we tested the in vitro membrane binding affin- loops of the phosphatase active site. The interface has
seven hydrophobic and aromatic residues forming aity of the E. coli produced M-CBR3 and M-ca2 PTEN
mutants using a published procedure (Fukuda et al., buried core, and nine residues that participate in net-
works of hydrogen bonds, several of which are made1996) that is a variation of the procedure we used for
the baculovirus-expressed PTEN. Figure 5F shows that with backbone groups (Figure 6A). The interface ele-
ments of the phosphatase domain are second only tothese mutants have reduced affinity for membranes in
vitro compared to E. coli produced wild-type PTEN. the P loop in conservation across species (Figure 1B),
and those of the C2 domain are the best conserved C2Taken together, these results strongly suggest that
PTEN binds to phospholipid membranes via its carboxy- regions (Figure 1B). The majority of the residues that
make interdomain hydrogen bonds have been foundterminal C2 domain and that its lipid binding activity is
important for its tumor suppressor function. However, mutated in cancer, and two of them, Ser-170 and Arg-
173, are among the eight most frequently mutated resi-additional functions for the PTEN C2 domain, such as
the protein binding demonstrated for one of the synapto- dues of PTEN (Figures 1B and 6A). These indicate that
the integrity of the interface is important for the functiontagmin C2 domains, cannot be ruled out.
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Table 1. Statistics from the Crystallographic Analysis
Data Set Native Hg l1 Hg l2 Hg l3
Wavelength (AÊ ) 1.0000 1.0091 1.0081 0.9920
Resolution (AÊ ) 2.1 2.7 2.7 2.7
Observations 188,143 108,117 108,062 108,067
Unique reflections 20,302 10,204 10,205 10,177
Data coverage (%) 95.8 98.3 98.4 98.1
Rsym (%) 3.7 4.8 5.4 6.0
MAD Analysis (10.0±3.0AÊ )
Phasing power 0.70 Ð 0.48 0.84
Rcullisa 0.93 Ð 0.97 0.87
Anomalous Rcullis Ð 0.76 0.77 0.80
Mean FOM 0.56
Refinement Statistics
Resolution (AÊ ) 15.0±2.1
Reflectionsb 20,302
Protein atoms 2,578
Water atoms 373
R factor (%)c 21.9
Rfree (%)d 25.7
Rmsd
Bonds (AÊ ) 0.010
Angles (8) 1.68
B factor (AÊ 2) 3.30
aRcullis is the mean residual lack of closure error divided by the dispersive or anomalous difference.
bReflections, |F| . 0 s.
cR factor 5 S | |F(obs)| 2 |F(calc)| |/S|F(obs)|.
dRfree 5 R factor calculated using 5.0% of the reflection data chosen randomly and omitted from the start of refinement.
of PTEN. Consistent with these observations, the Asp- with the phosphatase domain are similar in auxilin and
tensin (Figure 1B).252Tyr tumor-derived mutation, which occurs on the
C2 domain and would disrupt an interdomain hydrogen
bond network (Figure 6A), causes an 85% reduction in
Implications for PTEN Functionthe PI(3,4,5)P3 phosphatase activity (data not shown).
The structure reveals that PTEN has the dual specificityThe structural elements the PTEN C2 domain uses to
protein phosphatase fold but also has several activeinteract with the phosphatase domain are very similar
site characteristics that are divergent from those ofto the elements the PLCd1 C2 domain uses to pack
DSPs and PTPs. These include the insertion in the ªTIºwith its phospholipase domain (Figure 6B) (Essen et al.,
loop, the P loop residues Gly-129, Lys-125, Lys-128, and1996). Furthermore, PTEN and PLCd1 have a similar
the ªWPDº loop residue His-93. These PTEN-specificarrangement of their C2 domains relative to their active
features are evolutionarily conserved, are targeted bysites. In fact, when the two C2 domains are superim-
mutations in cancer, and their mutation reduces theposed, the PTEN and PLCd1 catalytic sites end up on
PI(3,4,5)P3 phosphatase activity of PTEN. Collectively,the same side and within 10 AÊ of each other (Figure 6B).
these observations indicate that the larger size and ba-This suggests that the C2 domains in the two proteins
sic charge of the active site are important for PI(3,4,5)P3may function similarly.
binding.
The structure also reveals that PTEN has a C2 domain,
and in conjunction with our biochemical and growthHomology to Tensin and Auxilin
The homology the PTEN phosphatase domain has with suppression data with PTEN mutants, it suggests that
this C2 domain may be involved in the association oftensin and auxilin (Li et al., 1997; Steck et al., 1997),
both of which lack key phosphatase active site residues, PTEN with the membrane. It has been proposed that a
three±amino acid sequence at the C terminus of PTENmaps primarily to the hydrophobic core and to residues
on the surface of the pa6 helix (Ser-170, Arg-173, Tyr- may bind to PDZ domains and help recruit PTEN to the
membrane (Teng et al., 1997), although the deletion of174, Tyr-177, and Leu-181). Since these pa6 helix resi-
dues pack with the C2 domain, their conservation raises this sequence does not significantly affect the growth
suppression activity of PTEN (Furnari et al., 1997; Georg-the possibility that tensin and auxilin may also contain
a C2 domain. In support of this hypothesis, we find that escu et al., 1999). The presence of multiple membrane
interaction modules would be reminiscent of many otherthe sequence following the phosphatase fold of auxilin
is most consistent with the structure of the PTEN C2 C2-containing proteins, including PLCd1 (Singer et al.,
1997). In PLCd1, the pleckstrin homology domain hasdomain, among the nearly 2000 structures analyzed with
the program THREADER2 (Miller et al., 1996). In this been shown to contribute to the initial membrane recruit-
ment, and the C2 domain has been suggested to fix thealignment, most of the PTEN C2 residues that interact
Crystal Structure of PTEN
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Phosphatase Assaysposition of the tightly linked catalytic domain on the
Lipid phosphatase assays were performed by the incubation of 100membrane (Essen et al., 1996). The PTEN phosphatase
mM PI (3,4,5)P3, PI(3,4)P2, PI(3)P (BIOMOL) with purified recombinantand C2 domains are similarly tightly linked, and this
PTEN in a 10 ml reaction mixture consisting of 100 mM Tris-HCl (pH
suggests that the PTEN C2 domain not only may help 8), 10 mM DTT, 1 mM phosphatidylserine at 378C. The reactions
recruit PTEN to the membrane, but it may also serve to were terminated by addition of 15 ml of ice-cold 100 mM N-ethylma-
leimide, and phospholipids were precipitated by centrifugationposition and orient the catalytic domain optimally with
(10,000 3 g, 15 min). Twenty microliters of the cleared supernatantrespect to the membrane-bound substrate. Our findings
was mixed with 80 ml of GREEN reagent (BIOMOL), and the concen-strongly support the model that the substrate important
tration of released phosphate was determined by measuring of OD atfor the tumor suppressor function of PTEN is the mem-
620 nm after 20 min of incubation at room temperature. Phosphatase
brane-bound PI(3,4,5)P3. activity of PTEN toward p-nitrophenylphosphate (pNPP) was deter-
mined as described (Maehama and Dixon, 1998). The phosphatase
assay using water-soluble diC8-PI(3,4,5)P3 (Echelon) and proteins im-Experimental Procedures
munoprecipitated from U87-MG cells with 1 mg anti-Myc 9E10 antibody
(Calbiochem) was done as described (Georgescu et al., 1999).Protein Overexpression and Purification
Human PTEN containing residues 7±353 and an internal deletion of
Cells, Transfection, Proliferation Assay, and Apoptosis Assayresidues 286±309 was overexpressed using a baculovirus vector in
Wild-type PTEN and the mutants were cloned in-frame with anHi5 (Invitrogen) insect cells. It was purified by anion exchange, cation
N-terminal Myc tag in the pCX retroviral vector (Georgescu et al.,exchange, and gel filtration chromatography and was concentrated
1999). U-87 MG glioblastoma cell line (ATCC) and Bosc23 retrovirus-to z20 mg/ml in 25 mM Tris-Cl, 0.4 M NaCl, 10 mM dithiothreitol
packaging cells were grown in Dulbecco's modified Eagle's medium(DTT) (pH 8.0). The full-length PTEN protein was prepared similarly.
with 10% fetal calf serum. The transfection of the Bosc23 cellsThe recombinant PTEN C2 domain (residues 183±353) and mutant
followed by the infection of U-87 MG glioblastoma cells with thePTEN proteins were overexpressed in E. coli as glutathione S-trans-
retrovirus-containing supernatants and the drug selection of stableferase (GST) fusion proteins, and they were purified by glutathione-
PTEN-expressing cells were done as described (Georgescu et al.,Sepharose (Pharmacia) affinity chromatography. K125M, K128M,
1999). For the proliferation assay, the cells growing in the 6 cmand K128R mutants were further purified as described (Maehama
dishes after complete selection were trypsinized and counted usingand Dixon, 1998). The cytosolic domain of synaptotagmin-I (Chap-
a hemocytometer. The soft agar colony assay was performed asman and Jahn, 1994) was overexpressed as a GST fusion protein,
described (Georgescu et al., 1999), and the size of colonies wascleaved with thrombin, and purified by anion exchange chromatog-
recorded 2 weeks after seeding. The protein expression levels wereraphy.
assayed in total cell lysates by Western blotting with anti-Myc anti-
body (Invitrogen).
Crystallization and Data Collection For the apoptosis assay, LNCaP human prostate carcinoma cell line
Crystals were grown at room temperature by the hanging-drop va- was transfected with wild-type or the crystallized fragment of PTEN
por diffusion method from 1.3 M Na/K L(1)-tartrate, 5%±10% (v/v) in pcDNA3.1, in the presence of a b-gal expression construct. Forty-
glycerol, 100 mM Tris-Cl, 10 mM DTT (pH 8.0). They form in space eight hours after transfection, the cells were fixed as described
group I4 with a 5 b 5 113.2 AÊ , c 5 56.9 AÊ and contain one molecule (Wang et al., 1999), and blue cells were scored under a microscope.
in the asymmetric unit. The native data set was collected using
crystals flash frozen in crystallization buffer supplemented with 25%
Acknowledgmentsglycerol at 21708C. The structure was determined using the multi-
wavelength anomalous diffraction (MAD) method with mercury-
We thank S. Geromanos and H. Erdjument-Bromage of the Sloan-derivatized crystals (Table 1). For the MAD data sets, crystals were
Kettering Microchemistry Facility for N-terminal sequence and masspretreated with 0.25% (v/v) glutaraldehyde for 30 min to reduce their
spectroscopic analyses; the staff of the Cornell High Energy Syn-tendency to crack and were soaked in 2 mM thimerosal for 1 hr
chrotron Source (MacChess) for help with data collection; T. Weberbefore being frozen.
for advice about the lipid binding assay; and C. Murray for adminis-
trative help. This work was supported by the Howard Hughes Medi-
Structure Determination and Refinement cal Institute, the National Institutes of Health, the Dewitt Wallace
Phasing was done by treating MAD as a special case of MIR. The Foundation, the Samuel and May Rudin Foundation, and the Walther
initial phases, calculated at 3.0 AÊ resolution with the program Cancer Institute. M. M. G. was supported by fellowships from the
MLPHARE (Table 1), were improved by density modification with Medical Research Council of Canada and the National Cancer Insti-
the program DM (Collaborative Computational Project, 1994). An tute (CA09673). P. P. is a scholar of the Leukemia Society of America.
initial model, built with the program O (Jones et al., 1991), was
improved by several cycles of manual rebuilding and refinement Received August 25, 1999; revised September 23, 1999.
with the program CNS (BruÈ nger et al., 1998). A strong (.3 s), continu-
ous Fo-Fc electron density in the active site could be modeled in
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